Bacterin International has launched OsteoSTX, a new novel allograft for orthopedic procedures.

Using Bacterin’s proprietary demineralization technology, the grafts are flexible cortical demineralized bone matrix matchsticks designed for multi-level and deformity spinal applications.

OsteoSTX is claimed to be the first product in Bacterin’s biologic portfolio designed specifically for addressing multi-level spine procedures and deformity cases.

Bacterin is the first company to market a product of this type for single use application.

Bacterin president and CEO Dan Goldberger said this is the first product Bacterin has launched since he joined the company, and he has been very pleased with the process and the results.

"We introduced this product to key opinion leaders at the NASS Evidence and Technology Spine Summit and the feedback was astounding," Goldberger added.

"I am looking forward to seeing how distribution of this new product will help support our growth goals, and complement our existing product portfolio."

OsteoSTX has already been implanted in patients with strong surgeon feedback supporting the use of the product and the application.

The product will be launched this week at the 2014 AAOS Conference in New Orleans, LA, March 12-14, 2014.